Pharmaceuticals
Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results
JIUQUAN, China, Feb. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ...
2022-02-12 06:05
6946
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient inChina in its multi-regi...
2022-02-11 20:40
4893
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in adolescents than in...
2022-02-11 10:45
4902
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission
SAN FRANCISCO, and SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) held a public Oncology Drug Advisory Committee (ODAC) for sintilimab, which is under review for the first-line treatment of people with non-squamous non-small cell lung cancer (nsqNSCLC) ba...
2022-02-11 10:44
4797
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, that the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052 (PD-L1/OX40 bispecific antibody) to initiate c...
2022-02-11 09:31
4547
Ucello Therapeutics Completes US$25 Million Series A Financing
SAN DIEGO, Calif. and CHENGDU, China, Feb. 10, 2022 /PRNewswire/ -- Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of aUS$25 million Series A financing. The funding round was led by Matrix Partners China, alon...
2022-02-11 02:16
2636
Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil
SEOUL, South Korea, Feb. 10, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, today announced that it has signed a supply deal with the Ministry of Health ofBrazil to deliver four million COVID-19 tests. Since January 2022, Brazil has battled a...
2022-02-10 20:00
3033
AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)
HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody (research and development code: AK115) injection developed in-house by the Company, has obtained approval from the Centre fo...
2022-02-10 17:00
2757
GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability
SINGAPORE, Feb. 10, 2022 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK), the world's leading life science research tools and services provider, today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services. The...
2022-02-10 16:34
9150
TABERNACLE HEALTH GROUP LAUNCHES CHINESE PROPRIETARY MEDICINE, AVROCIL (TM) COLD AND FLU AID
SINGAPORE, Feb. 10, 2022 /PRNewswire/ -- As we enter the cold and flu season,
it can be cumbersome to fall sick when the rest of the world is celebrating the
New Year.
2022-02-10 15:17
3794
Well Begun AND Half Done! - SIRONA Randomized Trial Achieves fifty percent enrollment
JENA, Germany, Feb. 10, 2022 /PRNewswire/ -- Concept Medical Inc.,
2022-02-10 08:21
3593
X-Chem and Excelra's GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets
LONDON and HYDERABAD, India, Feb. 9, 2022 /PRNewswire/ -- A new collaboration between data science and analytics leader, Excelra, and artificial intelligence pioneer X-Chem will accelerate preclinical drug discovery and aid scientists to find new drug candidates for currently hard-to-drug targets...
2022-02-09 22:00
4340
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres® Y-90 resin microspheres in China from the National Medical Products Administration
SIR-Spheres® Y-90 resin microspheres are the first therapeutic radiopharmaceutical approved by the NMPA in 2022 WOBURN, Mass., Feb. 9, 2022 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today with its shareholder, Grand Pharmaceut...
2022-02-09 21:30
2188
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...
2022-02-09 17:10
2736
CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia
* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation * Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chines...
2022-02-09 11:53
5282
Bugworks Research Inc. secures US$18M Series B1 Funding from Reputed Global Investor Syndicate (The EU, UK, Japan, South Africa & India), led by Lightrock India
This Funding will advance highly differentiated assets in the dual areas of Antimicrobial Resistance (AMR) and Immuno-Oncology (IO) BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 9, 2022 /PRNewswire/ -- Bugworks Research, a clinical stage multi-indication therapeutics company, ...
2022-02-09 10:00
11118
Cambrex Recognized with 2022 CMO Leadership Awards for the 8th Consecutive Year
EAST RUTHERFORD, N.J., Feb. 8, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service....
2022-02-08 22:30
3723
WuXi Biologics Statement
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries inShanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this a...
2022-02-08 11:08
4116
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals
NANJING, China, Feb. 7, 2022 /PRNewswire/ -- Simcere is thrilled to announce Bijoyesh Mookerjee, M.D., as our Chief Medical Officer, Oncology, of Simcere Pharmaceutical Group. Bijoyesh will be responsible for Simcere's oncology clinical pipeline strategy and development, enhancing our global res...
2022-02-08 10:01
2495
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...
2022-02-08 06:00
2425
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
15658
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
7518
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
7050
